Additionally, the shared molecular and immunological mechanisms between leishmaniasis and cancer, such as the role of immune checkpoints (e.g., CTLA-4, PD-L1) and pro-inflammatory pathways mediated by TLR signaling, open up novel avenues for therapeutic development (95). The gene discussed is CTLA4; the disease is cancer.